Advertisement Pharmaceutical Business review - Page 443 of 5222 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 7, 2024

AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy

AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.

Continue
Through this deal, AstraZeneca aims to bolster cardiovascular portfolio. Credit: Pexels from Pixabay.
October 4, 2024

FDA grants priority review for AstraZeneca’s Calquence sNDA

The FDA will provide a decision on Calquence for the treatment of previously untreated mantle cell lymphoma by the first quarter of 2025. Credit: Narupon Promvichai from Pixabay.
October 3, 2024

FDA grants fast track status for Volastra’s VLS-1488 to treat ovarian cancer

The trial will assess the safety, tolerability, and preliminary efficacy of the therapy. Credit: National Cancer Institute on Unsplash.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. FDA grants approval for Fresenius-Formycon’s biosimilar Otulfi
  2. AbbVie seeks FDA approval for non-small cell lung cancer treatment
  3. Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug
  4. MITEM PHARMA acquires global rights to injectable medicine from Novartis
  5. Amgen’s TEPEZZA gets Japan’s MHLW approval for thyroid eye disease treatment

PRESS RELEASES

Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer Remains on Track in First Half of 2024
Gerresheimer Remains on Track in First Half of 2024
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation